Survey emphasises a balanced and diverse diet to deal with the burgeoning obesity problem. It also recognises mental health as a principal factor in individual & national development.
Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.
Study, conducted by NCD Risk Factor Collaboration & WHO, shows that nearly 880 million adults globally living with obesity in 2022 — 4.5 times higher than the number recorded in 1990.
Study by Australian & Canadian scientists, published in Kidney International, finds that drug may be effective at reducing inflammation — lowering risk of heart & kidney disease.
In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.
Advisory by American Heart Association classifies cardiovascular-kidney-metabolic (CKM) syndrome into 4 stages, with therapeutic & screening strategies suggested for each.
There is also evidence that obesity is accompanied by brain inflammation and increased risk of mental health conditions such as major depressive disorder and anxiety.
The Army has plans for a technology thrust in the near term, including the use of AI to support decision-making. While well-intentioned, this may have unintended consequences.
COMMENTS